Voy at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Voy brings 6 presentations to ObesityWeek 2026 in National Harbor. Its program centres on predicting who responds to GLP-1 therapy in real-world use. Topics include baseline and early weight-loss predictors of results at twelve months, the uneven benefit of tirzepatide versus semaglutide, and the cost-effectiveness of tirzepatide paired with digital support.

OrganizationObesityWeek 2026 Attendance
Digital health
UK online weight-loss service that pairs prescribed GLP-1 medication with an app and clinical coaching.
Poster
Sat Nov 14
7:30pm–8:30pm
Precision Medicine for GLP-1 Therapy, Heterogeneous Benefit of Tirzepatide Vs Semaglutide
Chronic disease and obesity complicationsObesity pharmacotherapy and drug development
Talk
Mon Nov 16
10:10am–10:15am
Maximum Early-Period Weight Loss (Months 1–3) Predicts 12-Month GLP-1 Response in a Real-World Cohort
Metabolism and integrative physiologyNeuroscience of appetite and eatingInterventional and clinical studiesPopulation health and epidemiologyPolicy and public health

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Voy

Tell us what you sell and we’ll find the people at Voy most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction